Polycaprolactone scaffold as targeted drug delivery system and cell attachment scaffold for postsurgical care of limb salvage

Drug Delivery and Translational Research

Volumn 2, Issue 4, 2012, Pages 272-283

  Wong, Bin Sheng ^a   Teoh, Swee Hin ^b   Kang, Lifeng ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Nanyang Technological University   (Singapore)

Author keywords

Polycaprolactone; Scaffold; Targeted drug delivery; Tissue engineering

Indexed keywords

DOXORUBICIN; LIDOCAINE; MACROGOL DERIVATIVE; POLY(ETHYLENE GLYCOL) DIACRYLATE; POLYCAPROLACTONE; RHODAMINE B; TISSUE SCAFFOLD; UNCLASSIFIED DRUG;

ARTICLE; CELL ADHESION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; HUMAN; HUMAN CELL; LIMB SALVAGE; MATERIALS TESTING; NEEDLE; POSTOPERATIVE CARE; PRIORITY JOURNAL; SLOW RELEASE FORMULATION; TISSUE ENGINEERING; TISSUE REGENERATION;

EID: 84866147356     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-012-0096-9     Document Type: Article

References (50)

1. Lindell EB, Carroll NC. Limb salvage tumor surgery in children. Iowa Orthop J. 1993; 13: 124-35.
2. Messerschmitt PJ, Garcia RM, Abdul-Karim FW, Greenfield EM, Getty PJ. Osteosarcoma. J Am Acad Orthop Surg. 2009; 17(8): 515-27.
3. Carty CP, Dickinson IC, Watts MC, Crawford RW, Steadman P. Impairment and disability following limb salvage procedures for bone sarcoma. Knee. 2009; 16(5): 405-8.
4. Agins HJ, Alcock NW, Bansal M, Salvati EA, Wilson Jr PD, Pellicci PM, et al. Metallic wear in failed titanium-alloy total hip replacements. A histological and quantitative analysis. J Bone Joint Surg Am. 1988; 70(3): 347-56.
5. Lalor PA, Revell PA, Gray AB, Wright S, Railton GT, Freeman MA. Sensitivity to titanium. A cause of implant failure? J Bone Joint Surg Br. 1991; 73(1): 25-8.
6. Uhthoff HK, Finnegan M. The effects of metal plates on post-traumatic remodelling and bone mass. J Bone Joint Surg Br. 1983; 65(1): 66-71.
7. Yaremchuk MJ, Fiala TG, Barker F, Ragland R. The effects of rigid fixation on craniofacial growth of rhesus monkeys. Plast Reconstr Surg. 1994; 93(1): 1-10. discussion 1-5.
8. Sullivan PK, Smith JF, Rozzelle AA. Cranio-orbital reconstruction: safety and image quality of metallic implants on CT and MRI scanning. Plast Reconstr Surg. 1994; 94(5): 589-96.
9. Dhillon MS, Prabhakar S, Prasanna C. Preliminary experience with biodegradable implants for fracture fixation. Indian J Orthop. 2008; 42(3): 319-22.
10. Mankin HJ, Gebhardt MC, Jennings LC, Springfield DS, Tomford WW. Long-term results of allograft replacement in the management of bone tumors. Clin Orthop Relat Res. 1996; 324: 86-97.
11. Moore WR, Graves SE, Bain GI. Synthetic bone graft substitutes. ANZ J Surg. 2001; 71(6): 354-61.
12. Kurz LT, Garfin SR, Booth Jr RE. Harvesting autogenous iliac bone grafts. A review of complications and techniques. Spine (Phila Pa 1976). 1989; 14(12): 1324-31.
13. Schantz JT, Lim TC, Ning C, Teoh SH, Tan KC, Wang SC, et al. Cranioplasty after trephination using a novel biodegradable burr hole cover: technical case report. Neurosurgery. 2006; 58(1 Suppl): ONS-E176. discussion ONS-E176.
14. Schuckert KH, Jopp S, Teoh SH. Mandibular defect reconstruction using three-dimensional polycaprolactone scaffold in combination with platelet-rich plasma and recombinant human bone morphogenetic protein-2: de novo synthesis of bone in a single case. Tissue Eng Part A. 2009; 15(3): 493-9.
15. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, et al. Preoperative chemotherapy for osteogenic-sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982; 49(6): 1221-30.
16. Susa M, Iyer AK, Ryu K, Hornicek FJ, Mankin H, Amiji MM, et al. Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma. BMC Cancer. 2009; 9: 399.
17. Hogendoorn PC, Athanasou N, Bielack S, De Alava E, Dei Tos AP, Ferrari S, et al. Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5: v204-13.
18. Matsumine A, Takegami K, Asanuma K, Matsubara T, Nakamura T, Uchida A, et al. A novel hyperthermia treatment for bone metastases using magnetic materials. Int J Clin Oncol. 2011; 16(2): 101-8.
19. Gaur AH, Liu T, Knapp KM, Daw NC, Rao BN, Neel MD, et al. Infections in children and young adults with bone malignancies undergoing limb-sparing surgery. Cancer. 2005; 104(3): 602-10.
20. Goff BJ, Castillo R, Raja SN. Painful sequelae following limb salvage: etiology and management. J Am Acad Orthop Surg. 2011; 19 Suppl 1: S23-7.
21. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010; 75(1): 1-18.
22. Gou M, Zheng X, Men K, Zhang J, Zheng L, Wang X, et al. Poly(epsilon-caprolactone)/poly(ethylene glycol)/poly(epsilon-caprolactone) nanoparticles: preparation, characterization, and application in doxorubicin delivery. J Phys Chem B. 2009; 113(39): 12928-33.
23. Li X, Li R, Qian X, Ding Y, Tu Y, Guo R, et al. Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate. Eur J Pharm Biopharm. 2008; 70(3): 726-34.
24. Teo EY, Ong SY, Chong MS, Zhang Z, Lu J, Moochhala S, et al. Polycaprolactone-based fused deposition modeled mesh for delivery of antibacterial agents to infected wounds. Biomaterials. 2011; 32(1): 279-87.
25. Takada K. Microfabrication-derived DDS: from batch to individual production. Drug Discov Ther. 2008; 2(3): 140-55.
26. Lin W-J, Flanagan DR, Linhardt RJ. A novel fabrication of poly(ε-caprolactone) microspheres from blends of poly(ε-caprolactone) and poly(ethylene glycol)s. Polymer. 1999; 40(7): 1731-5.
27. Khademhosseini A, Vacanti JP, Langer R. Progress in tissue engineering. Sci Am. 2009; 300(5): 64-71.
28. Kim GH, Son JG. 3D polycarprolactone (PCL) scaffold with hierarchical structure fabricated by a piezoelectric transducer (PZT)-assisted bioplotter. Appl Phys A Mater. 2009; 94(4): 781-5.
29. Park SA, Lee SH, Kim WD. Fabrication of porous polycaprolactone/hydroxyapatite (PCL/HA) blend scaffolds using a 3D plotting system for bone tissue engineering. Bioprocess Biosyst Eng. 2011; 34(4): 505-13.
30. Baroli B. From natural bone grafts to tissue engineering therapeutics: brainstorming on pharmaceutical formulative requirements and challenges. J Pharm Sci. 2009; 98(4): 1317-75.
31. Mouriño V, Boccaccini AR. Bone tissue engineering therapeutics: controlled drug delivery in three-dimensional scaffolds. J R Soc Interface. 2010; 7(43): 209-27.
32. Kochhar JS, Goh WJ, Chan SY, Kang L. A simple method of microneedle array fabrication for transdermal drug delivery. Drug Dev Ind Pharm. 2012; in press.
33. Zhang JT, Keller TF, Bhat R, Garipcan B, Jandt KD. A novel two-level microstructured poly(N-isopropylacrylamide) hydrogel for controlled release. Acta Biomater. 2010; 6(10): 3890-8.
34. Tanaka N, Imai K, Okimoto K, Ueda S, Tokunaga Y, Ibuki R, et al. Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine (II): in vivo evaluation. J Control Release. 2006; 112(1): 51-6.
35. Mulye NV, Turco SJ. A simple-model based on first-order kinetics to explain release of highly water-soluble drugs from porous dicalcium phosphate dihydrate matrices. Drug Dev Ind Pharm. 1995; 21(8): 943-53.
36. Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation: I-theoretical consideration. Ind Eng Chem. 1931; 23: 923-31.
37. Rodrigues MR, Lanzarini CM, Ricci E. Preparation, in vitro characterization and in vivo release of naproxen loaded in poly-caprolactone nanoparticles. Pharm Dev Technol. 2011; 16(1): 12-21.
38. Chang HI, Perrie Y, Coombes AG. Delivery of the antibiotic gentamicin sulphate from precipitation cast matrices of polycaprolactone. J Control Release. 2006; 110(2): 414-21.
39. Gou M, Shi H, Guo G, Men K, Zhang J, Zheng L, et al. Improving anticancer activity and reducing systemic toxicity of doxorubicin by self-assembled polymeric micelles. Nanotechnology. 2011; 22(9): 095102.
40. Hee CK, Nicoll SB. Induction of osteoblast differentiation markers in human dermal fibroblasts: potential application to bone tissue engineering. Conf Proc IEEE Eng Med Biol Soc. 2006; 1: 521-4.
41. Notingher I, Jell G, Lohbauer U, Salih V, Hench LL. In situ non-invasive spectral discrimination between bone cell phenotypes used in tissue engineering. J Cell Biochem. 2004; 92(6): 1180-92.
42. Ramsey WS, Hertl W, Nowlan ED, Binkowski NJ. Surface treatments and cell attachment. In Vitro Cell Dev B. 1984; 20(10): 802-8.
43. Anselme K. Osteoblast adhesion on biomaterials. Biomaterials. 2000; 21(7): 667-81.
44. Sun HF, Mei L, Song CX, Cui XM, Wang PY. The in vivo degradation, absorption and excretion of PCL-based implant. Biomaterials. 2006; 27(9): 1735-40.
45. Morcuende JA, Gomez P, Stack J, Oji G, Martin J, Fredericks DC, et al. Effect of chemotherapy on segmental bone healing enhanced by rhBMP-2. Iowa Orthop J. 2004; 24: 36-42.
46. Friedlaender GE, Tross RB, Doganis AC, Kirkwood JM, Baron R. Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model. J Bone Joint Surg Am. 1984; 66(4): 602-7.
47. Bramwell VH, Steward WP, Nooij M, Whelan J, Craft AW, Grimer RJ, et al. Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: a European Osteosarcoma Intergroup study. J Clin Oncol. 1999; 17(10): 3260-9.
48. Souhami RL, Craft AW, van der Eijken JW, Nooij M, Spooner D, Bramwell VH, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet. 1997; 350(9082): 911-7.
49. Bramwell VH, Burgers M, Sneath R, Souhami R, van Oosterom AT, Voute PA, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol. 1992; 10(10): 1579-91.
50. Salerno M, Cenni E, Fotia C, Avnet S, Granchi D, Castelli F, et al. Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases. Curr Cancer Drug Targets. 2010; 10(7): 649-59.